

If any issues remain, the Examiner is urged to contact the undersigned by telephone for a prompt resolution thereof.

No additional fees are seen as being necessary in connection for this amendment. However, the Examiner is authorized to charge any additional fees or credit any overpayment to Deposit Account 50-1901.

Respectfully submitted,

August 8, 2002

  
\_\_\_\_\_  
Louis C. Cullman  
Registration No. 39,645

OPPENHEIMER WOLFF & DONNELLY LLP  
840 Newport Center Drive, Suite 700  
Newport Beach, CA 92660  
Telephone: 949.823.6000  
Facsimile: 949.823.6100



COPY OF PAPERS  
ORIGINALLY FILED

Serial No. 09/787810  
Atty. Docket: 21025.11

RECEIVED

AUG 19 2002

Version with markings to show changes made

In the claims:

Please amend claims 8 and 13 as follows:

TECH CENTER 1600/2900

8. (Amended) The composition as claimed in [any one of] Claim[s] 4 [to 7] wherein at least 50% by volume of the carrier particles have an effective particle size in the range of 30-150 micrometers.

13. (Amended) A pharmaceutical dosage form suitable for use with a dry powder inhaler comprising [micronised] micronized powdered colistin sulphomethate sodium wherein at least 90% by volume of the particles have a diameter less than 10 micrometers or a composition according to [any one of] Claim[s] 4 [to 11] and a container, said dosage having a content of below 10 wt % water.